Literature DB >> 29618501

Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage.

Cheryl Jennings1, Carrie G Wager2, Salvatore R Scianna3, Daniel J Zaccaro4, Amy Couzens4, John W Mellors5, Robert W Coombs6, James W Bremer3.   

Abstract

The National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Trials Group (ACTG) stores specimens from its clinical trials in a biorepository and permits the use of these specimens for nonprotocol exploratory studies, once the studies for the original protocol are concluded. We sought to assess the comparability of the data generated from real-time HIV-1 RNA testing during two clinical trials with the data generated from the retesting of different aliquots of the same samples after years of storage at -80°C. Overall, there was 92% agreement in the data generated for 1,570 paired samples (kappa statistic = 0.757; 95% confidence interval [CI], 0.716 to 0.797), where samples were tested in one laboratory using the microwell plate (MWP) version of the Roche HIV-1 Monitor test within 1 to 37 days of collection and retested in another laboratory using the Cobas version of the assay after a median of 6.7 years of storage (range, 5.7 to 8.6 years). Historical external quality control data submitted to the NIAID Virology Quality Assurance program (VQA) by client laboratories using the same two versions of the Monitor assay were used to differentiate between systematic differences in the assays to evaluate the stability of HIV-1 RNA in the stored samples. No significant loss of RNA was noted in samples containing either a low concentration (<50 copies/ml) or a high concentration (≥50 copies/ml) of HIV-1 RNA (P = 0.10 and P = 0.90, respectively) regardless of the time in storage. These data confirm the quality of the plasma samples in the ACTG biorepository following long-term storage.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HIV-1 RNA; RNA stability

Mesh:

Substances:

Year:  2018        PMID: 29618501      PMCID: PMC5971539          DOI: 10.1128/JCM.00120-18

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Effect of errors in the sequence of optical densities from the Roche AMPLICOR HIV-1 MONITOR assay on the validity of assay results.

Authors:  D J Brambilla; S Granger; C Jennings; J W Bremer
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Multisite comparison of reproducibility and recovery from the standard and ultrasensitive Roche AMPLICOR HIV-1 MONITOR assays.

Authors:  D J Brambilla; S Granger; C Jennings; J W Bremer
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Ratio of two successive optical densities from the Roche HIV-1 monitor test as a measure of accuracy of estimates of human immunodeficiency virus RNA concentration.

Authors:  Cheryl Jennings; Donald J Brambilla; James W Bremer
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR.

Authors:  N DiDomenico; H Link; R Knobel; T Caratsch; W Weschler; Z G Loewy; M Rosenstraus
Journal:  Clin Chem       Date:  1996-12       Impact factor: 8.327

5.  Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity.

Authors:  Christina M Lalama; Cheryl Jennings; Victoria A Johnson; Robert W Coombs; John E McKinnon; James W Bremer; Bryan R Cobb; Gavin A Cloherty; John W Mellors; Heather J Ribaudo
Journal:  J Clin Microbiol       Date:  2015-06-10       Impact factor: 5.948

6.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

7.  Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.

Authors:  Cheryl Jennings; Brian Harty; Suzanne Granger; Carrie Wager; John A Crump; Susan A Fiscus; James W Bremer
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

8.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1.

Authors:  K Triques; J Coste; J L Perret; C Segarra; E Mpoudi; J Reynes; E Delaporte; A Butcher; K Dreyer; S Herman; J Spadoro; M Peeters
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon.

Authors:  Jim F Huggett; Tanya Novak; Jeremy A Garson; Clare Green; Stephen D Morris-Jones; Robert F Miller; Alimuddin Zumla
Journal:  BMC Res Notes       Date:  2008-08-28
View more
  1 in total

Review 1.  Application of a Sanger-Based External Quality Assurance Strategy for the Transition of HIV-1 Drug Resistance Assays to Next Generation Sequencing.

Authors:  Cheryl Jennings; Neil T Parkin; Daniel J Zaccaro; Rupert Capina; Paul Sandstrom; Hezhao Ji; Donald J Brambilla; James W Bremer
Journal:  Viruses       Date:  2020-12-17       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.